{"name":"TD Vaccines A/S","slug":"td-vaccines-a-s","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"ACE527","genericName":"ACE527","slug":"ace527","indication":"Other","status":"phase_2"},{"name":"ACE527 vaccine","genericName":"ACE527 vaccine","slug":"ace527-vaccine","indication":"Other","status":"phase_1"}]},{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"ACE393","genericName":"ACE393","slug":"ace393","indication":"Cancer (specific indication under investigation in phase 2)","status":"phase_2"}]}],"pipeline":[{"name":"ACE393","genericName":"ACE393","slug":"ace393","phase":"phase_2","mechanism":"ACE393 is a therapeutic vaccine designed to stimulate immune responses against cancer cells by targeting tumor-associated antigens.","indications":["Cancer (specific indication under investigation in phase 2)"],"catalyst":""},{"name":"ACE527","genericName":"ACE527","slug":"ace527","phase":"phase_2","mechanism":"Biologic","indications":[],"catalyst":""},{"name":"ACE527 vaccine","genericName":"ACE527 vaccine","slug":"ace527-vaccine","phase":"phase_1","mechanism":"Biologic","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi4wFBVV95cUxNckdVUksyN19oeTR6amF5d285UVZFMU00ZTFudDVFeno4UjhmbU9sbzB5OUNrcEZDSE1DR0dpOGE1bTNGMXdUVDgwRUNaY0ZFcjlXWXVFVnV3VkVESHNaQ3FicFlCLTBxdkJMc1VXclI4MFpseklhMEFIYUo3cVoyMmo2ZTJtOXVMRmU2ZGY3WDhOTkdFaldKMHBDaGsxSGd1R0FqaDNTdUd2a1FvTkJoYTNXak9Sa29tWDdNbGl4QTFRT0JILXg1dTBoR2ZLQThvWjdvWnlqajM2LU9iSGM0cnBsSQ?oc=5","date":"2025-06-20","type":"pipeline","source":"Reuters","summary":"Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says - Reuters","headline":"Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says","sentiment":"neutral"}],"patents":[],"drugCount":3,"phaseCounts":{"phase_2":2,"phase_1":1},"enrichmentLevel":2,"visitCount":2,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}